CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-01 | Sethuraman Natarajan Chief Scientific Officer | Grant or award | +28,400 | 190,544 | ||
| 2023-03-01 | Sethuraman Natarajan Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +43,000 | 43,000 | ||
| 2023-03-01 | Doshi Dipal President and CEO | Grant or award | +99,300 | 261,135 | ||
| 2023-03-01 | Doshi Dipal President and CEO | Grant or award · Stock Option (Right to Buy) | +150,500 | 150,500 | ||
| 2023-03-01 | Dowden Nathan J Chief Operating Officer | Grant or award | +28,400 | 73,683 | ||
| 2023-03-01 | Dowden Nathan J Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +43,000 | 43,000 | ||
| 2023-03-01 | KREHER NERISSA Chief Medical Officer | Grant or award | +28,400 | 43,916 | ||
| 2023-03-01 | KREHER NERISSA Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +43,000 | 43,000 | ||
| 2023-02-28 | Doshi Dipal President and CEO | Sale | −2,000 | $12.00 | $24K | 161,835 |
| 2023-01-27 | Doshi Dipal President and CEO | Sale | −2,000 | $12.00 | $24K | 163,835 |
| 2023-01-09 | Doshi Dipal President and CEO | Sale | −2,410 | $15.02 | $36K | 165,835 |
| 2022-12-30 | KREHER NERISSA Chief Medical Officer | Sale | −5,200 | $13.45 | $70K | 15,516 |
| 2022-12-29 | Doshi Dipal President and CEO | Sale | −400 | $15.01 | $6K | 168,245 |
| 2022-12-28 | Doshi Dipal President and CEO | Sale | −4,521 | $15.01 | $68K | 168,645 |
| 2022-12-27 | Doshi Dipal President and CEO | Sale | −600 | $14.80 | $9K | 182,235 |
| 2022-12-27 | Doshi Dipal President and CEO | Sale | −9,069 | $15.04 | $136K | 173,166 |
| 2022-12-08 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise | +4,550 | $2.10 | $10K | 21,059 |
| 2022-12-08 | WENTWORTH KORY JAMES Chief Financial Officer | Sale | −4,550 | $18.95 | $86K | 16,509 |
| 2022-12-08 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −4,550 | 100,947 | ||
| 2022-12-05 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise | +200 | $2.10 | $420 | 16,709 |
Page 18 of 26 · 517 trades